A prospective study of tumor tissue specimens from newly diagnosed GBM patients treated with HIF2α inhibitors would shed light on the potential role of the HIF2α-ODZ1 cell migration-associated transcriptional pathway in disease progression. The gene discussed is TENM1; the disease is neoplasm.